4D Molecular Therapeutics: Market Expects Wet AMD Gene Therapy Failure - I'm Not So Sure [Seeking Alpha]
4D Molecular Therapeutics, Inc. (FDMT)
Company Research
Source: Seeking Alpha
Investing Group Leader Follow Play 14min Summary 4D Molecular Therapeutics' lead candidate, 4D-150, aims to provide a one-time gene therapy for Wet-AMD, showing promising but mixed Phase 2 data. Despite setbacks, 4D-150's potential for less frequent dosing and robust safety profile make it an intriguing investment, especially given 4D's strong cash position. The competitive landscape is fierce, with rivals like AbbVie and Adverum, but 4D-150 could still achieve significant market share if approved. Market sell-off appears overdone; 4D's well-funded position and diverse pipeline offer a compelling contrarian bet for risk-tolerant investors. welcomeinside Investment Overview I last covered 4D Molecular Therapeutics ( NASDAQ: FDMT ) in a deep dive note for Seeking Alpha back in July, when the Emeryville, California based biotech's share price took an almost 50% hit, falling from ~$27 per share to $14, after management shared data from its Phase 2 PRISM study of lea
Show less
Read more
Impact Snapshot
Event Time:
FDMT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FDMT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FDMT alerts
High impacting 4D Molecular Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
FDMT
News
- 4D Molecular Therapeutics, Inc. Is Being Investigated For Possible Securities Fraud And The Schall Law Firm Urges Impacted Investors To Reach OutAccesswire
- Shareholders Are Encouraged To Join The Schall Law Firm's Inquiry Into 4D Molecular Therapeutics Inc For Securities Related InfractionsAccesswire
- 4D Molecular Therapeutics, Inc. Is Being Investigated For Possible Securities Fraud And The Schall Law Firm Urges Impacted Investors To Reach OutAccesswire
- Shareholders Are Encouraged To Join The Schall Law Firm's Inquiry Into 4D Molecular Therapeutics Inc For Securities Related Infractions Accesswire
- 4D Molecular Therapeutics, Inc. Is Being Investigated For Possible Securities Fraud And The Schall Law Firm Invites Affected Investors To Reach Out Accesswire
FDMT
Earnings
- 5/9/24 - Beat
FDMT
Sec Filings
- 9/18/24 - Form 4
- 9/18/24 - Form 8-K
- 8/21/24 - Form 4
- FDMT's page on the SEC website